Browse by author
Lookup NU author(s): Dr Simon Tual-ChalotORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2026 The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.Background: Amyloid-beta 1–40 peptide (Aβ40) has recently emerged as a blood-based biomarker of cardiovascular disease (CVD). However, whether plasma levels of Aβ40 are associated with metabolic traits in humans without established CVD remains poorly understood. Methods: Aβ40 was measured in plasma by ELISA and metabolic traits (waist circumference, fasting triglycerides, fasting HDL cholesterol and fasting glucose) were determined in a general population (n = 449) of individuals who did not have clinically overt CVD. Triglyceride-glucose index (TyG) was used to calculate the risk for insulin resistance. BARD score was used to calculate the risk for metabolic liver disease. Results: Aβ40 levels were associated with the presence of metabolic syndrome (OR: 1.41 95% CI: 1.13–1.76, p =.003), and with higher odds for increasing incidence of metabolic syndrome components, characterized by decreased HDL-C levels (OR: 1.31 95% CI: 1.03–1.58, p =.017) and increased triglyceride levels (OR: 1.30 95% CI: 1.04–1.57, p =.033) after adjustment for traditional cardiovascular risk factors. Further, Aβ40 levels were associated with increased odds for TyG (OR: 1.26 95% CI: 1.03–1.57, p =.042) and increased odds for the presence of diabetes mellitus (OR: 1.35 95% CI: 1.04–1.76, p =.018) after adjustment for age and sex, smoking status, hypertension and dyslipidemia. Increased Aβ40 levels were associated with increased odds for BARD score ≥2 (OR: 1.41 95% CI: 1.04–2.04, p =.045) after adjustment for traditional cardiovascular risk factors. Conclusion: Our findings suggest that Aβ40 peptide is associated with metabolic traits and risk for metabolic disease. Future longitudinal studies are warranted to determine the prognostic value of Aβ40 for the development and progression of metabolic diseases.
Author(s): Sopova K, Delialis D, Aivalioti E, Georgiopoulos G, Athanasopoulos S, Zervas G, Konstantaki C, Sachse M, Sigl M, Duerschmied D, Tual-Chalot S, Stamatelopoulos K, Stellos K
Publication type: Article
Publication status: Published
Journal: European Journal of Clinical Investigation
Year: 2026
Volume: 56
Issue: 1
Online publication date: 08/01/2026
Acceptance date: 27/12/2025
Date deposited: 26/01/2026
ISSN (print): 0014-2972
ISSN (electronic): 1365-2362
Publisher: John Wiley and Sons Inc
URL: https://doi.org/10.1111/eci.70171
DOI: 10.1111/eci.70171
Data Access Statement: Anonymized data can be requested after publication of the results of prespecified analyses from the corresponding authors to be shared subject to approval of institutional review boards.
PubMed id: 41502294
Altmetrics provided by Altmetric
